PSMD10 and hepatocellular carcinoma: Considering that Gankyrin expression levels progressively increase within multistep HCC carcinogenesis and that Gankyrin overexpression begins at the chronic hepatitis stage, we hypothesize that silencing Gankyrin at the chronic hepatitis or cirrhosis stage might impair hepatocarcinogenesis; this possibility will be further explored in future studies.